Antiparasitic drugs for paediatrics : systematic review, formulations, pharmacokinetics, safety, efficacy and implications for control
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 1022825
Author(s) Keiser, Jennifer; Ingram, Katrin; Utzinger, Jürg
Author(s) at UniBasel Utzinger, Jürg
Keiser, Jennifer
Year 2011
Title Antiparasitic drugs for paediatrics : systematic review, formulations, pharmacokinetics, safety, efficacy and implications for control
Journal Parasitology
Volume 138
Number 12
Pages / Article-Number 1620-32
Keywords Antiparasitic drugs, antimalarials, anthelminthics, preventive chemotherapy, paediatrics, infants, children, adolescence, systematic review, drug formulation
Abstract SUMMARYDrug development for paediatric applications entails a number of challenges, such as the wide age spectrum covered - from birth to adolescence - and developmental changes in physiology during biological maturation that influence the efficacy and toxicity of drugs. Safe and efficacious antiparasitic drugs for children are of pivotal importance given the large proportion of burden attributable to parasitic diseases in this age group, and growing efforts to administer, as widely as possible, antiparasitic drugs to at-risk populations, such as infants and school-aged children, often without prior diagnosis. The purpose of this review is to investigate whether antiparasitic drugs have been adequately studied for use in paediatrics. We approached this issue through a systematic review using PubMed and the Cochrane Central Register of Trials covering a period of 10 years and 8 months until the end of August 2010 to identify trials that investigated efficacy, safety and pharmacokinetic (PK) parameters of antiparasitic drugs for paediatrics. Overall, 269 clinical drug trials and 17 PK studies met our inclusion criteria. Antimalarial drugs were the most commonly studied medicines (82.6%). Most trials were carried out in Africa and children aged 2-11 years were the age group most often investigated. Additionally, we critically examined available drug formulations for anthelminthics and identified a number of shortcomings that are discussed. Finally, we shed new light on current proposals to expand 'preventive chemotherapy' to preschool-aged children and emphasise that new research, including risk-benefit analyses, are needed before such a strategy can be adopted more widely
Publisher Cambridge University Press
ISSN/ISBN 0031-1820
edoc-URL http://edoc.unibas.ch/dok/A6002112
Full Text on edoc No
Digital Object Identifier DOI 10.1017/S0031182011000023
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/21349223
ISI-Number WOS:000295970000018
Document type (ISI) Journal Article, Review
 
   

MCSS v5.8 PRO. 0.706 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
08/08/2020